Pancreatic Carcinoma

Oncology
2
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Knight Therapeutics
Knight TherapeuticsQC - Montréal
2 programs
1
Botulinum Toxin Type APhase 21 trial
Non-Interventional StudyN/A1 trial
Active Trials
NCT06084013Recruiting55Est. Feb 2026
NCT04965311Terminated4Est. Jul 2024
CT
1 program
1
TQB2858 injectionPhase 11 trial
Active Trials
NCT05193604TerminatedEst. Nov 2023

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Knight TherapeuticsBotulinum Toxin Type A
Chia Tai TianQing Pharmaceutical GroupTQB2858 injection
Knight TherapeuticsNon-Interventional Study

Clinical Trials (3)

Total enrollment: 59 patients across 3 trials

NCT04965311Knight TherapeuticsBotulinum Toxin Type A

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

Start: Mar 2023Est. completion: Jul 20244 patients
Phase 2Terminated

A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma

Start: Mar 2022Est. completion: Nov 2023
Phase 1Terminated
NCT06084013Knight TherapeuticsNon-Interventional Study

Use Of Indocyanine Green In Pancreas Surgery

Start: May 2024Est. completion: Feb 202655 patients
N/ARecruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 59 patients
2 companies competing in this space